Multiple Choice
The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
A) ESAs no longer be prescribed to patients with chronic renal failure
B) The risk of tumor development be explained to cancer patients on ESA therapy
C) Patients should no longer receive ESA therapy to prepare for allogenic transfusions
D) ESAs be prescribed only to patients younger than age 60 years
Correct Answer:
Verified
Correct Answer:
Verified
Q2: For patients taking warfarin, INRs are best
Q3: Juanita had a deep vein thrombosis (DVT)
Q4: Robert, age 51 years, has been told
Q5: Kenneth is taking warfarin and is asking
Q6: Monitoring for a patient being prescribed iron
Q8: Patients receiving heparin therapy require monitoring of:<br>A)
Q9: Patient education when prescribing clopidogrel includes:<br>A) Do
Q10: Education of patients who are taking warfarin
Q11: Patient education regarding taking iron replacements includes:<br>A)
Q12: The average starting dose of warfarin is